Clinical Efficacy of Tirellizumab Combined with Cisplatin in the Treat-ment of Advanced Non-small Cell Lung Cancer
Objective To explore the effect of tirellizumab and cisplatin chemotherapy in advanced non-small cell lung cancer.Methods A total of 384 patients with advanced non-small cell lung cancer admitted to the Department of Respiratory and Critical Care Medicine,Yancheng First Hospital Affiliated to Nanjing University School of Medicine from July 2021 to June 2023 were conveniently selected as the study objects,and were divided into control group(n=192)and study group(n=192)by sealed envelope method.The control group received cisplatin chemotherapy,and the study group received intravenous tirellizumab on this basis.Before and after 4 cycles of treatment,to check and calcu-late the two groups of neutrophils/lymphocyte ratio(NLR),platelet/lymphocyte ratio(PLR),systemic immune-inflammation index(SII)levels;the clinical efficacy and incidence of adverse reactions were compared between pa-tients in two groups.Results The remission rate of disease in the study group was higher than that in the control group,the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in levels of in-flammatory response between patients in two groups(P>0.05).After treatment,NLR was(2.05±1.19),PLR was(123.58±29.32)and SII was(158.56±31.73)in the study group were lower than those in the control group,the differ-ences were statistically significant(t=5.674,6.828,18.476,all P<0.001).The incidence of adverse reactions in study group was lower than that in control group,and the difference was statistically significant(P<0.05).Conclusion Tirelli-zumab combined with cisplatin can improve the therapeutic effect,reduce inflammation,and reduce adverse reactions in patients with advanced non-small cell lung cancer with high safety.
NETL
NSTL
万方数据
